NIH is issuing an Intramural Research Program (IRP) policy to promote access to IRP-supported inventions resulting in drugs, biologics, vaccines, or devices. As of June 1, 2025, organizations applying to NIH for certain commercial patent licenses will be required to submit Access Plans to NIH outlining steps they intend to take to promote patient access to those licensed products. NIH will continue working with industry partners to develop additional resources and guidance in support of these efforts.

For more information see the OSP Innovation and Translation policy page.

Questions may be sent to SciencePolicy@od.nih.gov 

If you are not yet a subscriber you can sign up to the to the OSP_News mailing list.  Also, please consider following us on X @NIH_OSP  and LinkedIn.